Ensign Peak Advisors Inc Decreases Stock Position in Humana Inc. (NYSE:HUM)

Ensign Peak Advisors Inc trimmed its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 44.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 405,457 shares of the insurance provider's stock after selling 319,796 shares during the quarter. Ensign Peak Advisors Inc owned 0.34% of Humana worth $102,868,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Principal Financial Group Inc. increased its stake in shares of Humana by 2.4% during the third quarter. Principal Financial Group Inc. now owns 170,636 shares of the insurance provider's stock worth $54,047,000 after buying an additional 3,961 shares during the period. Nordea Investment Management AB increased its position in shares of Humana by 6.6% in the 4th quarter. Nordea Investment Management AB now owns 9,679 shares of the insurance provider's stock valued at $2,487,000 after purchasing an additional 602 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Humana by 1.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,848 shares of the insurance provider's stock valued at $2,245,000 after purchasing an additional 138 shares in the last quarter. Ridgewood Investments LLC lifted its position in shares of Humana by 15.8% during the 4th quarter. Ridgewood Investments LLC now owns 1,026 shares of the insurance provider's stock worth $260,000 after purchasing an additional 140 shares during the last quarter. Finally, Atlas Brown Inc. grew its stake in shares of Humana by 0.6% during the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider's stock worth $1,611,000 after purchasing an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Trading Down 1.5 %

NYSE:HUM opened at $249.67 on Friday. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock's 50 day simple moving average is $265.21 and its 200-day simple moving average is $270.30. The firm has a market cap of $30.13 billion, a P/E ratio of 25.09, a PEG ratio of 2.05 and a beta of 0.49.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.07 by $1.51. Humana had a net margin of 1.02% and a return on equity of 11.70%. The company had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. During the same period in the previous year, the company posted $7.23 EPS. Humana's revenue was up 8.4% compared to the same quarter last year. Equities analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a yield of 1.42%. Humana's payout ratio is currently 25.04%.

Analysts Set New Price Targets

HUM has been the subject of a number of recent analyst reports. Guggenheim began coverage on Humana in a report on Wednesday, April 9th. They set a "buy" rating and a $326.00 price target for the company. Barclays boosted their target price on Humana from $270.00 to $322.00 and gave the stock an "equal weight" rating in a research note on Friday, April 11th. Raymond James raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target for the company in a report on Thursday, May 1st. Truist Financial raised their price objective on shares of Humana from $290.00 to $325.00 and gave the stock a "hold" rating in a report on Friday, April 11th. Finally, StockNews.com upgraded shares of Humana from a "hold" rating to a "buy" rating in a report on Friday. Seventeen research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Humana presently has an average rating of "Hold" and a consensus price target of $287.76.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.